Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$689M |
| 2 |
Broadcom
AVGO
|
+$153M |
| 3 |
Walmart Inc
WMT
|
+$136M |
| 4 |
Amazon
AMZN
|
+$104M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$102M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$71.5M |
| 2 |
Pinnacle West Capital
PNW
|
+$49.1M |
| 3 |
Procter & Gamble
PG
|
+$43.7M |
| 4 |
Chevron
CVX
|
+$43.1M |
| 5 |
Hershey
HSY
|
+$43M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.62% |
| 2 | Healthcare | 9.42% |
| 3 | Industrials | 7.55% |
| 4 | Financials | 6.82% |
| 5 | Consumer Discretionary | 6.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Amneal Pharmaceuticals
AMRX
$6.24B
| $10.4M | 0.08% |
825,999
+83,186
| +11% | +$952K |
|
252
Cognizant
CTSH
$27.9B
| $10.4M | 0.08% |
125,272
+89,189
| +247% | +$6.67M |
|
253
California Water Service
CWT
$3.06B
| $10.3M | 0.08% |
+238,840
| New | +$10.9M |
|
254
Celanese
CE
$5.14B
| $10.3M | 0.08% |
242,788
+209,936
| +639% | +$8.56M |
|
255
A.O. Smith
AOS
$8.57B
| $10.2M | 0.08% |
152,894
+103,215
| +208% | +$6.97M |
|
256
Dianthus Therapeutics
DNTH
$6.21B
| $10.2M | 0.08% |
+246,788
| New | +$9.57M |
|
|
B
257
Barrick Mining
B
$78.3B
| $10.1M | 0.08% |
232,590
+180,059
| +343% | +$6.76M |
|
258
Alcoa
AA
$13.7B
| $10M | 0.08% |
188,960
-1,608
| -0.8% | -$65.8K |
|
259
Onto Innovation
ONTO
$17.9B
| $10M | 0.08% |
63,362
-37,300
| -37% | -$5.3M |
|
260
ICU Medical
ICUI
$4.57B
| $9.99M | 0.08% |
69,993
+62,441
| +827% | +$8.36M |
|
261
ITT
ITT
$18.6B
| $9.98M | 0.08% |
57,523
+37,779
| +191% | +$6.77M |
|
262
EyePoint Inc
EYPT
$459M
| $9.94M | 0.08% |
+544,077
| New | +$7.71M |
|
263
Crane NXT
CXT
$2.89B
| $9.88M | 0.08% |
+210,004
| New | +$12.4M |
|
264
Kimco Realty
KIM
$16.1B
| $9.86M | 0.08% |
486,544
+235,221
| +94% | +$4.88M |
|
265
Trane Technologies
TT
$99.8B
| $9.71M | 0.08% |
+24,961
| New | +$10.3M |
|
266
Relay Therapeutics
RLAY
$4.26B
| $9.66M | 0.08% |
+1,141,880
| New | +$8.15M |
|
267
Baxter International
BAX
$13.6B
| $9.62M | 0.08% |
503,628
+199,339
| +66% | +$3.99M |
|
268
BridgeBio Pharma
BBIO
$15.9B
| $9.58M | 0.08% |
125,302
+94,874
| +312% | +$6.23M |
|
269
TSMC
TSM
$2.17T
| $9.57M | 0.08% |
31,497
-59,726
| -65% | -$17.5M |
|
|
CWAN
270
DELISTED
Clearwater Analytics
CWAN
| $9.51M | 0.07% |
+394,445
| New | +$7.9M |
|
271
American Electric Power
AEP
$65.8B
| $9.5M | 0.07% |
+82,380
| New | +$9.73M |
|
272
Houlihan Lokey
HLI
$9.02B
| $9.41M | 0.07% |
54,025
+37,274
| +223% | +$6.84M |
|
273
Toast
TOST
$21.2B
| $9.4M | 0.07% |
+264,785
| New | +$9.55M |
|
274
CoStar Group
CSGP
$13.1B
| $9.37M | 0.07% |
+139,296
| New | +$9.87M |
|
|
CNH
275
CNH Industrial
CNH
$19.1B
| $9.32M | 0.07% |
1,011,270
-306,010
| -23% | -$3.06M |
|
Similar funds
Michael Gelband's Q4 2025 Portfolio in Review
As of Q4 2025, Michael Gelband held 2,189 positions worth $12.7B, up 30% from $9.79B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Michael Gelband deployed $2.85B of net new capital in Q4 2025, opening 723 new positions and adding to 409 existing holdings. Its largest new stake was iShares Core S&P 500 ETF: 150,000 shares worth $103M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 15% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was Procter & Gamble, an estimated $43.7M trimmed.
- Michael Gelband's largest Q4 2025 buy was iShares Core S&P 500 ETF: 150,000 shares worth $103M.
- Michael Gelband added most to NVIDIA in Q4 2025, an estimated $689M increase.
- Michael Gelband's biggest Q4 2025 reduction was Procter & Gamble, cutting an estimated $43.7M.
- Michael Gelband fully exited Meta Platforms (Facebook) in Q4 2025, selling an estimated $71.5M.
- Michael Gelband's ten largest holdings make up 30% of its $12.7B portfolio in Q4 2025.
- Michael Gelband opened 723 new positions and closed 716 in Q4 2025.
- Michael Gelband's portfolio value rose 30% quarter-over-quarter to $12.7B.
Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.